FELIX study results reveal obe-cel’s potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.
FDA approves major depressive drug after rejecting it multiple times in past two decades
The FDA approved a Houston drugmaker’s tablet for adults with major depressive disorder last week, capping a decades-long back-and-forth between multiple companies and the regulator
September 29, 2023